Avantax Advisory Services’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$569K Buy
15,793
+2,394
+18% +$79.3K ﹤0.01% 1508
2025
Q1
$417K Buy
13,399
+85
+0.6% +$2.69K ﹤0.01% 1624
2024
Q4
$340K Buy
13,314
+115
+0.9% +$3.05K ﹤0.01% 1703
2024
Q3
$373K Sell
13,199
-890
-6% -$24.7K ﹤0.01% 1604
2024
Q2
$372K Buy
+14,089
New +$391K ﹤0.01% 1558

Other funds holding RPRX

Avantax Advisory Services's RPRX Position: Q2 2025 in Review

Avantax Advisory Services increased its Royalty Pharma (RPRX) stake by 18% in Q2 2025, buying an estimated $79.3K and bringing the position to 15,793 shares worth $569K. The position accounts for ﹤0.01% of the portfolio, ranked #1508.

Avantax Advisory Services first reported a position in RPRX in Q2 2024 and has held it in 5 quarters since. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Avantax Advisory Services held 15,793 shares of Royalty Pharma worth $569K as of Q2 2025.
  • Avantax Advisory Services bought 2,394 Royalty Pharma shares in Q2 2025, an estimated $79.3K.
  • Royalty Pharma made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #1508 holding.
  • Avantax Advisory Services first reported a position in Royalty Pharma in Q2 2024 and has held it in 5 quarters since.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.